Quantitative Analysis of Parkinsonian Tremor in a Clinical Setting Using Inertial Measurement Units

الملخص EN

Background.

Parkinson’s disease (PD) is a neurodegenerative disorder that affects human voluntary movements.

Tremor is one of the most common symptoms of PD and is expressed as involuntary oscillation of the body.

Tremors can be analysed in the frequency domain.

Objective.

The aim of the current study was to examine selected tremor parameters (frequency, root mean square, and approximated entropy) in order to quantify the characteristics of patients diagnosed with PD, compared to a healthy control group, and to compare the parameters by dividing the subjects according to UPDRS assessment.

Methods.

The subjects were divided into two groups: a group of people diagnosed with PD (n = 19) and a control group consisting of healthy volunteers (CO = 12).

Each subject performed motor tasks specific to certain tremors: the finger-to-nose test.

Each subject performed a motor task three times.

A nine degree of freedom (DOF) wireless inertial measurement unit was used for the measurement of upper limb motor tasks.

For the quantitative estimation of kinetic and postural tremors, dominant frequency, root means square, and approximation entropy were selected and calculated from the measured angular velocity and linear acceleration signals.

A one-way ANOVA with a significance level of α = 0.05 was used to test the null hypothesis that the means of the tremor metrics were the same between the PD and CO groups.

Results.

Statistically significant differences between PD patients and control groups were observed in ApEn acceleration signal of kinetic tremor, ApEn angular velocity signal of kinetic tremor, ApEn angular velocity of postural tremor, frequency acceleration signal of postural tremor, and RMS angular speed kinetic tremor.

Conclusion.

Application of inertial measurement units for clinical research of patients and PD tremor evaluation allows providing quantitative information for diagnostic purposes, during screening in a clinical setting that differentiates between PD patients and controls.